Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Net assets


Fully diluted NAV per share


NAV total return


Life science portfolio return


Capital pool available to invest in life science


% of net assets invested in life science


HY2018 Business Catalysts

  • Continued positive sales progress in Blue Earth
  • Data read-outs in seven ongoing clinical trials; two new clinical trials expected to commence
  • New financings, companies and programme initiations